Takeda Pharmaceutical (NYSE:TAK) Upgraded to “Hold” at Zacks Research

Zacks Research upgraded shares of Takeda Pharmaceutical (NYSE:TAK) from a strong sell rating to a hold rating in a research report released on Tuesday morning,Zacks.com reports.

A number of other research firms have also issued reports on TAK. Morgan Stanley assumed coverage on Takeda Pharmaceutical in a report on Tuesday, January 13th. They set an “overweight” rating on the stock. Weiss Ratings reiterated a “hold (c-)” rating on shares of Takeda Pharmaceutical in a research report on Monday, December 29th. Finally, Wall Street Zen upgraded Takeda Pharmaceutical from a “hold” rating to a “strong-buy” rating in a report on Saturday, January 31st. One equities research analyst has rated the stock with a Buy rating and two have issued a Hold rating to the stock. According to MarketBeat, Takeda Pharmaceutical presently has a consensus rating of “Hold”.

Takeda Pharmaceutical Stock Down 2.7%

TAK traded down $0.50 on Tuesday, reaching $17.72. The company’s stock had a trading volume of 2,282,851 shares, compared to its average volume of 3,081,065. The company has a market capitalization of $56.39 billion, a price-to-earnings ratio of 73.84 and a beta of 0.01. Takeda Pharmaceutical has a fifty-two week low of $12.99 and a fifty-two week high of $18.82. The company has a quick ratio of 0.65, a current ratio of 1.19 and a debt-to-equity ratio of 0.56. The stock has a 50 day moving average of $17.11 and a two-hundred day moving average of $15.42.

Takeda Pharmaceutical (NYSE:TAK) last posted its earnings results on Thursday, January 29th. The company reported $0.95 earnings per share for the quarter, beating the consensus estimate of $0.55 by $0.40. The business had revenue of $6.75 billion during the quarter, compared to the consensus estimate of $7.81 billion. Takeda Pharmaceutical had a return on equity of 10.60% and a net margin of 2.58%. As a group, analysts forecast that Takeda Pharmaceutical will post 1.64 EPS for the current fiscal year.

Hedge Funds Weigh In On Takeda Pharmaceutical

Several large investors have recently added to or reduced their stakes in the business. Dynasty Wealth Management LLC bought a new position in Takeda Pharmaceutical during the third quarter valued at about $706,000. Capital Fund Management S.A. raised its stake in shares of Takeda Pharmaceutical by 216.1% in the second quarter. Capital Fund Management S.A. now owns 126,279 shares of the company’s stock valued at $1,952,000 after purchasing an additional 86,333 shares in the last quarter. Vise Technologies Inc. bought a new position in Takeda Pharmaceutical in the second quarter worth $1,247,000. Vestmark Advisory Solutions Inc. bought a new position in Takeda Pharmaceutical in the second quarter worth $987,000. Finally, ABC Arbitrage SA acquired a new stake in Takeda Pharmaceutical during the third quarter worth $8,372,000. 9.17% of the stock is currently owned by hedge funds and other institutional investors.

About Takeda Pharmaceutical

Takeda Pharmaceutical Company Limited (NYSE: TAK) is a Tokyo-based, multinational biopharmaceutical company with roots dating back to 1781. The company researches, develops, manufactures and commercializes pharmaceutical and biopharmaceutical products for patients worldwide. Takeda is publicly listed and operates as a fully integrated R&D-driven healthcare company focused on delivering specialty medicines and therapies across a range of therapeutic areas.

Takeda’s main business activities encompass discovery and development of prescription medicines, clinical development and regulatory affairs, manufacturing of small molecules and biologics, and global commercial operations.